Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo
Study Title
- A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Teva Identifier
- MS-GA-301 | 2009-018084-27
ClinicalTrials.gov Identifier
- NCT01067521
Study Status
- Completed
Trial Condition(s)
- Relapsing Remitting Multiple Sclerosis
Interventions
- Drug: Glatiramer acetate (GA) | Drug: Placebo
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 55 Years
Trial Duration
- June 22, 2010 - May 12, 2017
Phase
- Phase 3
Study Type
Interventional
